Solara Active Pharma Sciences Limited (NSE: SOLARA, BSE: 541540) is a Chennai, Tamil Nadu-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹2,951 Cr, it ranks #1,022 by market cap among the 6,189 Indian listed companies on FinBizNet, and #5 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹611.55 (as of 26 Oct 2026), the share price is 21.0% below its 52-week high of ₹774.00 and 44.9% above its 52-week low of ₹422.00. The share price is up 3.3% over one year and up 24.3% over three months.
| Current Price | ₹611.55 |
|---|---|
| Market Cap | ₹2,951 Cr |
| NSE Symbol | SOLARA |
| BSE Code | 541540 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | -363.4 |
| Return on Equity | -0.63% |
| Return on Assets | 2.41% |
| 52-Week Range | ₹422.00 – ₹774.00 |
| 1-Year Price Change | +3.3% |
| 3-Month Price Change | +24.3% |
| Beta (1Y) | 0.14 |
| Dividend Yield | 0.00% |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.solara.co.in |
| Revenue | ₹417 Cr |
|---|---|
| Net Profit | ₹28 Cr |
| Net Margin | 6.8% |
| EPS (Basic) | ₹5.92 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-retroviral, antibiotic, anticonvulsant, antidepressant, antifibrinolytics, antigout agent, antihelmintic, antihistamine, antihyperlipoproteinemic, antimycotic, antifungal, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antiulcer, antiulcerative, anxiolytic, aprepitant, bile acid analogue, calcimimetic agent, cardiovascular agent, chronic alcoholism, treatment of hyperphosphatemia, hemorrheologic agent, hypercholesterolemia, hypophosphatemic agent, immun
1. Manufacture and Sale of Active Pharma Ingredients-This segment develops, manufactures, and sells active pharmaceutical ingredients. It also provides contract manufacturing and development services.
1. Active Pharmaceutical Ingredient-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,70,481 Cr | 70.1 | 16.98% | ₹4,979 Cr | +28.0% |
| Aether Industries Limited | ₹18,748 Cr | 85.4 | 9.81% | ₹327 Cr | +88.8% |
| Alivus Life Sciences Ltd | ₹15,350 Cr | 27.2 | 18.36% | ₹640 Cr | +33.8% |
| Aarti Pharmalabs Ltd | ₹7,443 Cr | 42.6 | 8.49% | ₹536 Cr | -4.1% |
| Solara Active Pharma Sciences Limited | ₹2,951 Cr | -363.4 | -0.63% | ₹417 Cr | +3.3% |
| Sai Parenteral's Limited | ₹2,040 Cr | 105.9 | 2.88% | ₹179 Cr | — |
| KRM Ayurveda Limited | ₹508 Cr | 25.2 | — | ₹32 Cr | — |
| Trident Lifeline Limited | ₹486 Cr | 24.9 | — | — | +39.4% |
| Infinium Pharmachem Limited | ₹446 Cr | 36.7 | — | — | +13.5% |
Listed by market capitalisation. Ratios are shown for context only.
Solara Active Pharma Sciences Limited is trading at ₹611.55, with a market capitalisation of ₹2,951 Cr.
Solara Active Pharma Sciences Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Solara Active Pharma Sciences Limited has a P/E of -363.4 and a return on equity of -0.63%.
Solara Active Pharma Sciences Limited is listed on the NSE under the symbol SOLARA and on the BSE under the scrip code 541540.
Solara Active Pharma Sciences Limited's share price is up 3.3% over one year and up 24.3% over three months. Its 52-week range is ₹422.00 to ₹774.00.
In Q2 FY27, Solara Active Pharma Sciences Limited reported revenue of ₹417 Cr and net profit of ₹28 Cr, with basic EPS of ₹5.92 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.